FY2025 · ended Dec 31, 2025 · Revenue $1.54B, +0.5% YoY · Filed Feb 26, 2026
Lantheus Holdings, Inc. (LNTH) files with the SEC under industry code 2835, In Vitro & In Vivo Diagnostic Substances. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $1.5 billion and net income of $233.6 million. As of Jun 30, 2026 it held $593.3 million in cash and investments and $55.7 million in total debt.
Revenue (TTM)
$1.56B
+2.3% vs year-ago TTM
Net income (TTM)
$275.31M
+1.6% vs year-ago TTM
Operating cash flow (TTM)
$412.80M
-21.7% vs year-ago TTM
Free cash flow
$259.92M
+1093.3% vs prior year
EPS (TTM)
$4.16
+10.3% vs year-ago TTM
Dividend per share
None
Shares outstanding
64.61M
-5.7% vs prior year
Net cash
$537.59M
as of Jun 30, 2026
Operating margin
19.4%
FY 2026
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- LNTH (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Bedford, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1521036
- Former names
- Lantheus MI Holdings, Inc. (until May 23, 2014)
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Neogen Corp NEOG
- Celldex Therapeutics, Inc. CLDX
- Intellia Therapeutics, Inc. NTLA
- QuidelOrtho Corp QDEL
- Achieve Life Sciences, Inc. ACHV
- Myriad Genetics Inc MYGN
- Alpha Teknova, Inc. TKNO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $1.5B | $1.5B | $1.3B | $935.1M | $425.2M |
| Operating income | $310.8M | $457.0M | $364.6M | $36.2M | -$60.8M |
| Net income | $233.6M | $312.4M | $326.7M | $28.1M | -$71.3M |
| Diluted EPS | $3.41 | $4.36 | $4.65 | $0.40 | -$1.06 |
| Operating cash flow | $390.1M | $544.8M | $305.3M | $281.8M | $53.9M |
| Free cash flow | — | — | $259.9M | $21.8M | $53.9M |
| Total assets | $2.2B | $2.0B | $1.7B | $1.3B | $863.8M |
| Total liabilities | $1.1B | $892.3M | $835.3M | $874.1M | $399.3M |
| Stockholders' equity | $1.1B | $1.1B | $815.9M | $447.1M | $464.4M |
| Cash and investments | $359.1M | $912.8M | $713.7M | $415.7M | $98.5M |
| Total debt | $55.8M | $57.7M | $58.6M | $586.3M | $193.6M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Oct 22, 2026 | Oct 21, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Oct 14, 2026 | Oct 14, 2026 |
| 8-K |
Current report
Other events
|
Oct 2, 2026 | Oct 2, 2026 |
| 8-K |
Current report
Other events
|
Sep 21, 2026 | Sep 17, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
All 1000 Lantheus Holdings, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.